Output details

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection

There have been extensive publications on the role of PET in lymphoma, but this was the first paper to evaluate the prognostic value of PET/CT in HIV-positive patients with Hodgkin lymphoma. We concluded that a PET scan early in the treatment cycle predicts response and progression-free survival in this patient group and, very importantly, provides a basis on which to investigate whether response-adapted treatment strategies can improve outcomes. This was a multi-centre trial across 5 UK centres with Warbey leading the PET aspects of the study. The paper has been published in one of the leading infectious disease journals.